A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Risk of Major Bleeding Associated With Apixaban Verses Warfarin in the Treatment of Venous Thromboembolism in US Clinical Practice

A study to compare the risk of a major bleeding in participants who received 2 different blood thinning medications following a blood clot

Inclusion Criteria:

• An acute-care inpatient encounter with a principal or secondarydiagnosis of VTE, or an ambulatory-care encounter with any diagnosis of VTE
• An outpatient pharmacy claim for apixaban or warfarin during the 30-day period following the index encounter
• Continuous and comprehensive medical/drug coverage for ≥6 months preceding the index encounter

Exclusion Criteria:

• Evidence of a trial fibrillation/flutter or chemotherapy/radiation therapy for malignancy (other than non-melanoma skin cancer) during 6-month period preceding first receipt of index therapy
• Evidence of VTE(VTE event)during 6-month period preceding index encounter
• Evidence of malignancy (other than non-melanoma skin cancer) during 90-day period preceding first receipt of index therapy

Other protocol defined inclusion/exclusion criteria could apply